Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.

Lok, Anna S; Gardiner, David F; Hézode, Christophe; Lawitz, Eric J; Bourlière, Marc; Everson, Gregory T; Marcellin, Patrick; Rodriguez-Torres, Maribel; Pol, Stanislas; Serfaty, Lawrence; Eley, Timothy; Huang, Shu-Pang; Li, Jianling; Wind-Rotolo, Megan; Yu, Fei; McPhee, Fiona; Grasela, Dennis M; Pasquinelli, Claudio

Lok, Anna S; Gardiner, David F; Hézode, Christophe; Lawitz, Eric J; Bourlière, Marc; Everson, Gregory T; Marcellin, Patrick; Rodriguez-Torres, Maribel; Pol, Stanislas; Serfaty, Lawrence; Eley, Timothy; Huang, Shu-Pang; Li, Jianling; Wind-Rotolo, Megan; Yu, Fei; McPhee, Fiona; Grasela, Dennis M; Pasquinelli, Claudio.

Affiliation

Lok AS; Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA. Electronic address: aslok@med.umich.edu.
Gardiner DF; Bristol-Myers Squibb, Hopewell, NJ, USA.
Hézode C; Hôpital Henri Mondor, AP-HP, Université Paris-Est, Créteil, France.
Lawitz EJ; The Texas Liver Institute, University of Texas Health Sciences Center, San Antonio, TX, USA.
Bourlière M; Hôpital Saint-Joseph, Marseille, France.
Everson GT; University of Colorado Denver, Aurora, CO, USA.
Marcellin P; Hôpital Beaujon, Clichy, France.
Rodriguez-Torres M; Fundación de Investigación, San Juan, PR, USA.
Pol S; Hôpital Cochin, Paris, France.
Serfaty L; Hôpital Saint-Antoine, Paris, France.
Eley T; Bristol-Myers Squibb, Hopewell, NJ, USA.
Huang SP; Bristol-Myers Squibb, Princeton, NJ, USA.
Li J; Bristol-Myers Squibb, Princeton, NJ, USA.
Wind-Rotolo M; Bristol-Myers Squibb, Princeton, NJ, USA.
Yu F; Bristol-Myers Squibb, Wallingford, CT, USA.
McPhee F; Bristol-Myers Squibb, Wallingford, CT, USA.
Grasela DM; Bristol-Myers Squibb, Hopewell, NJ, USA.
Pasquinelli C; Bristol-Myers Squibb, Hopewell, NJ, USA.

J Hepatol ; 60(3): 490-9, 2014 Mar.

Article in En | MEDLINE | ID: mdl-24444658

Subject(s)

Antiviral Agents/administration & dosage; Hepatitis C, Chronic/drug therapy; Imidazoles/administration & dosage; Isoquinolines/administration & dosage; Sulfonamides/administration & dosage; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic/virology; Humans; Interferon alpha-2; Interferon-alpha/administration & dosage; Male; Middle Aged; Polyethylene Glycols/administration & dosage; Pyrrolidines; Recombinant Proteins/administration & dosage; Ribavirin/administration & dosage; Valine/analogs & derivatives

Key words

ALT; AST; DAA; Direct-acting antiviral agents; HCV; HCV NS5A inhibitor; Hepatitis C treatment; LLOQ; LOD; Non-responders; PegIFNα; Protease inhibitor; QUAD; RBV; SNP; SVR; SVR(12); SVR(24); SVR(4); Sustained virologic response; alanine aminotransferase; aspartate aminotransferase; direct-acting antiviral; hepatitis C virus; limit of detection; lower limit of quantification; pegylated interferon alfa-2a; quadruple; ribavirin; single nucleotide polymorphism; sustained virologic response; sustained virologic response at 12weeks post-treatment; sustained virologic response at 24weeks post-treatment; sustained virologic response at 4weeks post-treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Sulfonamides / Hepatitis C, Chronic / Imidazoles / Isoquinolines Type of study: Clinical_trials Limits: Female / Humans / Male / Middle aged Language: En Journal: J Hepatol Journal subject: GASTROENTEROLOGIA Year: 2014 Type: Article

Fulltext

XML

PubMed Links

Search on Google